	US 12,350,303 B2
	Oncolytic virus therapy
Zong Sheng Guo, Wexford, PA (US); David Bartlett, Pittsburgh, PA (US); Zuqiang Liu, Wexford, PA (US); and Mathilde Feist, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Appl. No. 16/482,623
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
PCT Filed Feb. 5, 2018, PCT No. PCT/US2018/016912 § 371(c)(1), (2) Date Jul. 31, 2019, PCT Pub. No. WO2018/145033, PCT Pub. Date Aug. 9, 2018.
Claims priority of provisional application 62/454,526, filed on Feb. 3, 2017.
Prior Publication US 2020/0000862 A1, Jan. 2, 2020
Int. Cl. A61K 38/20 (2006.01); A61K 35/761 (2015.01); A61K 35/763 (2015.01); A61K 35/768 (2015.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); C07K 14/55 (2006.01); C12N 7/01 (2006.01)

CPC A61K 35/763 (2013.01) [A61K 35/761 (2013.01); A61K 35/768 (2013.01); A61K 38/191 (2013.01); A61K 38/2013 (2013.01); A61K 38/217 (2013.01)]

4 Claims

1. An oncolytic virus comprising, in its genome, a nucleic acid encoding a membrane-associated fusion protein comprising an immunomodulator molecule directly linked to an anchoring peptide via a rigid linker, wherein:

the immunomodulator molecule comprises SEQ ID NO: 13 or SEQ ID NO: 13 with one or two amino acid variations;

the oncolytic virus is a vaccinia virus;

the nucleic acid is operably linked to an oncolytic virus promoter;

the rigid linker is a peptide linker between 1 and 25 amino acids in length; and

the anchoring peptide comprises a GPI-anchor acceptor peptide.